儿童Ross手术:自体移植物的长期命运
本研究回顾性分析了1991至2024年间单中心226例18岁以下接受Ross或Ross-Konno手术的患者,中位随访9.5年。结果显示除新生儿外各组30年生存率超过90%,Shone综合征和复杂先心病死亡风险显著增加。25年免于自体移植物再干预率为82%,免于RV-PA管道再干预率为66%,出院时轻度以上主动脉瓣反流与17倍的自体移植物干预风险相关。
要点
- 儿童Ross手术长期生存和瓣膜耐久性良好,孤立性主动脉瓣病变者获益最佳
- Shone综合征和复杂先心病死亡风险分别增加11倍和8.8倍
- 自体移植物扩张和管道再干预是重要晚期风险,需终身随访
核心结论
- Ross手术在儿童和青少年中提供优异的长期生存和瓣膜耐久性,尤其适用于孤立性主动脉瓣病变患者。
- 自体移植物扩张和管道再干预仍是重要晚期风险,强调需在专科中心终身监测。
研究设计与样本
- 回顾性单中心队列研究,纳入1991至2024年间所有连续<18岁接受Ross或Ross-Konno手术的患者,共226例,中位年龄8.5岁,67%为男性,中位随访9.5年(IQR 12.7)。
主要发现
- 手术死亡率为2%,总死亡率为5%;除新生儿外所有组30年生存率超过90%,新生儿5年生存率为60%。
- 校正年龄后,Shone综合征和复杂先心病分别与死亡风险增加11倍和8.8倍相关(P < .03)。
- 25年免于自体移植物再干预率为82%,免于RV-PA管道再干预率为66%。
- 20年免于严重自体移植物扩张(绝对尺寸>50 mm)率为71%,按体表面积指数化(>25 mm/m2)时为54%。
- 出院时大于轻度主动脉瓣反流与自体移植物干预风险增加17倍相关(P < .001)。
临床怎么用
- 对于儿童和青少年主动脉瓣病变,Ross手术可提供良好的长期结局,尤其孤立性病变者应优先考虑。
- Shone综合征和复杂先心病患者术后死亡风险显著增高,需加强随访和风险管理。
- 出院时存在大于轻度主动脉瓣反流者再干预风险高,应密切监测。
- 所有患者需终身监测自体移植物扩张和RV-PA管道功能,建议在专科中心随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Ross operation achieves excellent outcomes in children and adolescents, but the influence of age at surgery and underlying pathology on long-term results remains uncertain. Evidence on autograft dilatation necessitating reintervention is also limited. This study aimed to identify patient groups best served from the Ross procedure and to evaluate long-term autograft performance. METHODS: All consecutive patients <18 years undergoing a Ross or Ross-Konno procedure between 1991 and 2024 at a single centre were analysed. Demographic, operative, and follow-up data were collected. Patients were stratified into age groups (neonate, infant, child, adolescent) and diagnostic groups (isolated aortic valve disease, aortic stenosis with subaortic stenosis, Shone's complex, and complex congenital heart disease [CHD]). Outcomes included overall survival, freedom from autograft and right ventricle-pulmonary artery (RV-PA) conduit reintervention, and severe autograft dilatation (>50 mm or >25 mm/m2). RESULTS: A total of 226 patients underwent surgery at a median age of 8.5 years; 67% were male. Median follow-up was 9.5 years (IQR 12.7). Operative mortality was 2% and overall mortality 5%. Survival exceeded 90% at 30 years in all groups except neonates (60% at 5 years). After adjustment for age, Shone's complex and complex CHD were associated with an 11-fold and 8.8-fold increased hazard of death, respectively (P < .03). Freedom from autograft reintervention was 82% and from RV-PA conduit reintervention was 66% at 25 years. Freedom from severe autograft dilatation was 71% at 20 years by absolute dimension and 54% when indexed to BSA. Greater than mild aortic regurgitation at discharge conferred a 17-fold risk of autograft intervention (P < .001). CONCLUSIONS: The Ross procedure provides excellent long-term survival and valve durability in children and adolescents, particularly those with isolated aortic valve disease. Autograft dilatation and conduit reintervention remain important late risks, reinforcing the need for lifelong surveillance in specialised centres.
引用
- Hussein N, Ramcharan T, George J, et al. The Ross Operation in Children-What Is the Long-Term Fate of the Autograft? Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42371763. doi:10.1093/icvts/ivag176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。